Loading data for TLSA — first visit, this takes a few seconds.
Tiziana Life Sciences Ltd (TLSA)
NasdaqCM: TLSA
· Real-Time Price · USD
1.15
+0.01 (0.88%)
At close: Aug 27, 2026, 8:00 PM
1.09
+0.93%
After-hours: 4:42 PM
The price, the headline numbers and the latest news, in one place.
Tiziana Life Sciences Ltd (TLSA) Stock Price, Analysis & Data
0.88% (1D)
No data available
| Bid | 1.13 |
| Market Cap | 137.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.43M |
| 0.46 | |
| -0.16 | |
| n/a | |
| -5.41 | |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.11 |
| Volume | 884,970 |
| Avg. Volume (20D) | 520,293 |
| Open | 1.14 |
| Previous Close | 1.14 |
| Day's Range | 1.14 - 1.25 |
| 52-Week Range | 0.87 - 2.35 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TLSA
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2018
Employees 10
Stock Exchange NasdaqCM
Ticker Symbol TLSA
Financial Performance
In 2025, Tiziana Life Sciences Ltd's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -18.43M, an increase of 55.37%.
Financial StatementsEarnings Surprise
Tiziana Life Sciences Ltd has released their quarterly earnings on Dec 27, 2022:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of -0.06 misses estimates by , with -Infinity% YoY decline.
Page 1 of 2